Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stevo Julius

Showing results (21-30 of 118) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|September 7, 2010
Angiotensin-receptor blockade, cancer, and concernsStevo Julius, Sverre E Kjeldsen, Michael A Weber
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
Prehypertension: should we be treating with pharmacologic therapy?Brent M Egan, Shawna D Nesbitt, Stevo Julius
Current Opinion in Cardiology|August 2, 2002
Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studiesKarin Skov, Stevo Julius, Shawna Nesbitt, et al.
Blood Pressure|July 8, 2020
Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-StudyMagnus Holanger, Sverre E Kjeldsen, Kenneth Jamerson, et al.
Statistics in Medicine|December 17, 2008
A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropoutsNiko A Kaciroti, M Anthony Schork, Trivellore Raghunathan, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 20, 2006
Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophySverre E Kjeldsen, Arne Strand, Stevo Julius, et al.
The American Journal of Cardiology|October 10, 2006
Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension?Franz H Messerli, Sripal Bangalore, Brent M Egan, et al.
Blood Pressure|August 28, 2014
Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial LectureSverre E Kjeldsen, Stevo Julius, Björn Dahlöf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 7, 2012
Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressureEmily B Levitan, Niko Kaciroti, Suzanne Oparil, et al.
Journal of the American Society of Hypertension : JASH|April 23, 2010
TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertensionStevo Julius, Niko Kaciroti, Brent M Egan, et al.
Pageof 12

Showing results (21-30 of 118) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|September 7, 2010
Angiotensin-receptor blockade, cancer, and concernsStevo Julius, Sverre E Kjeldsen, Michael A Weber
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
Prehypertension: should we be treating with pharmacologic therapy?Brent M Egan, Shawna D Nesbitt, Stevo Julius
Current Opinion in Cardiology|August 2, 2002
Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studiesKarin Skov, Stevo Julius, Shawna Nesbitt, et al.
Blood Pressure|July 8, 2020
Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-StudyMagnus Holanger, Sverre E Kjeldsen, Kenneth Jamerson, et al.
Statistics in Medicine|December 17, 2008
A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropoutsNiko A Kaciroti, M Anthony Schork, Trivellore Raghunathan, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 20, 2006
Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophySverre E Kjeldsen, Arne Strand, Stevo Julius, et al.
The American Journal of Cardiology|October 10, 2006
Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension?Franz H Messerli, Sripal Bangalore, Brent M Egan, et al.
Blood Pressure|August 28, 2014
Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial LectureSverre E Kjeldsen, Stevo Julius, Björn Dahlöf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 7, 2012
Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressureEmily B Levitan, Niko Kaciroti, Suzanne Oparil, et al.
Journal of the American Society of Hypertension : JASH|April 23, 2010
TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertensionStevo Julius, Niko Kaciroti, Brent M Egan, et al.
Pageof 12